MARKET

YMAB

YMAB

Y-Mabs Therapeutics
NASDAQ
4.420
-0.390
-8.11%
Opening 13:32 03/31 EDT
OPEN
4.650
PREV CLOSE
4.810
HIGH
4.710
LOW
4.390
VOLUME
148.89K
TURNOVER
--
52 WEEK HIGH
17.78
52 WEEK LOW
4.250
MARKET CAP
199.86M
P/E (TTM)
-6.6049
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at YMAB last week (0324-0328)?
Weekly Report · 8h ago
Weekly Report: what happened at YMAB last week (0317-0321)?
Weekly Report · 03/24 09:07
Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views
Benzinga · 03/21 18:01
Y-mAbs Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/21 12:36
Y-mAbs Therapeutics Price Target Cut to $12.00/Share From $22.00 by HC Wainwright & Co.
Dow Jones · 03/21 12:36
HC Wainwright & Co. Maintains Buy on Y-mAbs Therapeutics, Lowers Price Target to $12
Benzinga · 03/21 12:28
Y-Mabs Therapeutics: Promising Pipeline and Positive Financial Outlook Justify Buy Rating
TipRanks · 03/21 10:36
Y-mAbs Therapeutics price target lowered to $12 from $22 at H.C. Wainwright
TipRanks · 03/21 10:31
More
About YMAB
More
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT), and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas.
Recently
Symbol
Price
%Change

Webull offers Y-mAbs Therapeutics Inc stock information, including NASDAQ: YMAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, YMAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading YMAB stock methods without spending real money on the virtual paper trading platform.